BC Week In Review | Jun 15, 2018
Clinical News

Vical discontinuing HSV-2 program after Phase II miss

Vical Inc. (NASDAQ:VICL) said it will discontinue development of VCL-HB01 after the HSV-2 vaccine missed the primary endpoint in a Phase II trial. VCL-HB01 is a plasmid DNA vaccine that encodes the HSV-2 glycoprotein D...
BC Extra | Jun 11, 2018
Clinical News

Vical discontinuing HSV-2 program after Phase II miss

Vical Inc. (NASDAQ:VICL) sank $0.43 (26%) to $1.20 on Monday after the company said it will discontinue development of VCL-HB01 after the HSV-2 vaccine missed the primary endpoint in a Phase II trial. VCL-HB01 is...
BC Week In Review | Jan 26, 2018
Clinical News

Astellas/Vical CMV vaccine ASP0113 fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the international Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. The...
BC Extra | Jan 22, 2018
Clinical News

Astellas/Vical CMV vaccine fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. Vical sank...
BioCentury | Jan 13, 2018
Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Innovations | Dec 22, 2017
Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
BC Week In Review | Jun 2, 2017
Clinical News

Vical completes enrollment in Phase II of HSV-2 vaccine

In April, Vical Inc. (NASDAQ:VICL) completed enrollment of 225 adults with symptomatic genital herpes simplex virus type 2 (HSV-2) infection in a Phase II trial evaluating 1 mL intramuscular VCL-HB01 (HSV-2 vaccine, Vaxfectin-formulated plasmid DNA...
BC Extra | Feb 28, 2017
Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

Merck & Co. Inc. (NYSE:MRK) said it will submit applications in the U.S. and EU this year for letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation...
BC Week In Review | Oct 10, 2016
Clinical News

Herpes simplex virus type 2: Phase II started

Vical began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 1 mL intramuscular VCL-HB01 every 28 days for 4 doses in about 225 patients. Vical Inc. (NASDAQ:VICL), San Diego, Calif.   Product: Herpes simplex...
Items per page:
1 - 10 of 512
BC Week In Review | Jun 15, 2018
Clinical News

Vical discontinuing HSV-2 program after Phase II miss

Vical Inc. (NASDAQ:VICL) said it will discontinue development of VCL-HB01 after the HSV-2 vaccine missed the primary endpoint in a Phase II trial. VCL-HB01 is a plasmid DNA vaccine that encodes the HSV-2 glycoprotein D...
BC Extra | Jun 11, 2018
Clinical News

Vical discontinuing HSV-2 program after Phase II miss

Vical Inc. (NASDAQ:VICL) sank $0.43 (26%) to $1.20 on Monday after the company said it will discontinue development of VCL-HB01 after the HSV-2 vaccine missed the primary endpoint in a Phase II trial. VCL-HB01 is...
BC Week In Review | Jan 26, 2018
Clinical News

Astellas/Vical CMV vaccine ASP0113 fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the international Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. The...
BC Extra | Jan 22, 2018
Clinical News

Astellas/Vical CMV vaccine fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. Vical sank...
BioCentury | Jan 13, 2018
Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Innovations | Dec 22, 2017
Product R&D

Dengvaxia’s warning

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...
BC Week In Review | Jun 2, 2017
Clinical News

Vical completes enrollment in Phase II of HSV-2 vaccine

In April, Vical Inc. (NASDAQ:VICL) completed enrollment of 225 adults with symptomatic genital herpes simplex virus type 2 (HSV-2) infection in a Phase II trial evaluating 1 mL intramuscular VCL-HB01 (HSV-2 vaccine, Vaxfectin-formulated plasmid DNA...
BC Extra | Feb 28, 2017
Clinical News

Merck CMV prophylaxis headed for U.S., EU submissions

Merck & Co. Inc. (NYSE:MRK) said it will submit applications in the U.S. and EU this year for letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation...
BC Week In Review | Oct 10, 2016
Clinical News

Herpes simplex virus type 2: Phase II started

Vical began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 1 mL intramuscular VCL-HB01 every 28 days for 4 doses in about 225 patients. Vical Inc. (NASDAQ:VICL), San Diego, Calif.   Product: Herpes simplex...
Items per page:
1 - 10 of 512